-Background -Proton-pump inhibitors have been used for at least two decades. They are among the most commonly sold drugs in the world. However, some controversy remains about the indications for their use and the consequences of their prolonged use. Objectives -To evaluate and compare the endoscopic and histopathologic gastric changes in chronic users of proton-pump inhibitors to changes in non-users. Methods -A prospective study performed at a tertiary Public Hospital involving 105 patients undergoing upper-gastrointestinal endoscopy. Subjects included 81 proton-pump inhibitor users and 24 non-users (control group).Biopsies of the antral-type mucosa, the antral-fundic transition, and the fundus were evaluated by the Sydney System. The presence of erosion or ulceration, lymphatic follicles, reactive gastropathy, and polypoid or epithelial hyperplasia was also determined. Serum levels of gastrin were measured. Results -We found two polyps, one in each group, both of which were negative for Helicobacter pylori. There were two cases of parietal cell hyperplasia in users of proton-pump inhibitors. Gastrin was elevated in 28 users of proton-pump inhibitors and in four members of the control group. We did not find statistically significant differences in the endoscopic or histopathologic findings between the two groups. Conclusion -Chronic use of proton-pump inhibitors for the duration examined was not associated with significant gastric changes. An interesting finding was that the 4 chronic users of proton-pump inhibitors who had serum gastrin levels above 500 pg/mL also had positive serology for Chagas disease.
Background:Morbid obesity is a multifactorial disease that increasingly is being treated by
surgery. Aim: To evaluate gastric histopathological changes in obese, and to compare with
patients who underwent gastrojejunal bypass and the jejunal mucosa after the
surgery. Methods:This is an observational study performed at a tertiary public hospital, evaluating
endoscopic biopsies from 36 preoperative patients and 35 postoperative. Results:In the preoperative group, 80.6% had chronic gastritis, which was active in 38.9%
(77.1% and 20.1%, respectively, in the postoperative). The postoperative group had
a significant reduction in H. pylori infection (p=0.0001). A longer length of the
gastric stump and a time since surgery of more than two years were associated with
Helicobacter pylori infection. The jejunal mucosa was normal in 91.4% and showed
slight nonspecific chronic inflammation in 8.6%. Conclusion:There was a reduction in the incidence of Helicobacter pylori infection in the
postoperative group. A longer length of the gastric stump and longer time elapsed
since surgery were associated with Helicobacter pylori infection. The jejunal
mucosa was considered normal in an absolute majority of patients.
Background: Acid inhibition from chronic proton pump inhibitor use and a possible increase in gastrin can lead to changes in the regulation of hydrochloric acid production. However, it has not known whether such chronic use changes the presence of gastrin, delta, and enterochromaffin-like cells in the stomach or the relationship between gastrin and delta cells. Aim: To analyze the number of gastrin-producing gastrin cells, somatostatin-producing cells, and histamine-producing cells in patients who were chronic users of proton pump inhibitor, with or without related Helicobacter pylori infection. Methods: Biopsies from 105 patients, including 81 chronic proton pump inhibitor users (experimental group) and 24 controls, were processed immunohistochemically and subjected to counting of gastrin, delta, and enterochromaffin-like cells in high-magnification microscopic fields and in 10 glands. Results: Gastrin cell, delta cell, and enterochromaffin-like cells counts were similar across the groups and appeared to be unaffected by Helicobacter pylori infection. The ratio between gastrin cells and delta cells was higher in the chronic users of proton pump inhibitor group than in controls. Conclusion: Chronic users of proton pump inhibitor does not affect gastrin cell, delta cell, and enterochromaffin-like cell counts significantly, but may alter the ratio between gastrin cells and delta cells.
Ovarian neoplasms are among the most common in the female genital tract and often have delayed
diagnosis. Tumor progression involves signalling proteins called galectins. The aim of the present study
was to evaluate the immunohistochemical expression of galectins “1”, “3” and “9” in the ovarian surface
epithelial neoplasia. A retrospective study involving 62 ovarian epithelial tumors (benign and non-benign)
was performed with immunohistochemical polymer technique and antibodies against galectin “1”, “3” and
“9”. Expression in epithelium and stroma was analysed semi-quantitatively. Fisher’s exact test was
performed for statistical analysis. Galectin-“1” and “3” were strongly expressed in non-benign tumors of
the epithelium. Non-benign neoplasms showed increased stromal expression of galectin-1 and increased
epithelial expression of galectin-“3”. The significant increase in expression of galectin-1 and -3 in the
epithelium of non- benign ovarian neoplasms suggests the participation of these galectins in ovarian
carcinogenesis. We observed increased stromal expression of galectin-“1” and epithelial expression of
galectin-“3” in non-benign ovarian neoplasms. These findings contribute to knowledge about the role of
these galectins in the growth and spread of ovarian cancer.
- There was a reduction in the incidence of Helicobacter pylori infection in the postoperative group. A longer length of the gastric stump and longer time elapsed since surgery were associated with Helicobacter pylori infection. The jejunal mucosa was considered normal in an absolute majority of patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.